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Multiple sclerosis (MS) is an immune-mediated disorder of the central nervous system 
that results in destruction of the myelin sheath that surrounds axons and eventual 
neurodegeneration. Current treatments approved for the treatment of relapsing forms 
of MS target the aberrant immune response and successfully reduce the severity of 
attacks and frequency of relapses. Therapies are still needed that can repair damage 
particularly for the treatment of progressive forms of MS for which current therapies are 
relatively ineffective. Remyelination can restore neuronal function and prevent further 
neuronal loss and clinical disability. Recent advancements in our understanding of the 
molecular and cellular mechanisms regulating myelination, as well as the development 
of high-throughput screens to identify agents that enhance myelination, have lead to the 
identification of many potential remyelination therapies currently in preclinical and early 
clinical development. One problem that has plagued the development of treatments to 
promote remyelination is the difficulty in assessing remyelination in patients with current 
imaging techniques. Powerful new imaging technologies are making it easier to discern 
remyelination in patients, which is critical for the assessment of these new therapeu-
tic strategies during clinical trials. This review will summarize what is currently known 
about remyelination failure in MS, strategies to overcome this failure, new therapeutic 
treatments in the pipeline for promoting remyelination in MS patients, and new imaging 
technologies for measuring remyelination in patients.
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iNTRODUCTiON
The therapeutic armamentarium for multiple sclerosis (MS) has expanded significantly in the 
last few decades due to better understanding of the basic pathophysiological mechanisms of the 
disease process. However, despite the development of increasingly effective therapies, a cure for 
MS has not been found and MS patients continue to suffer from chronic progressive disability. 
Currently, approved treatments for MS work by reducing immune system activity or blocking 
entry of immune cells into the central nervous system (CNS). Although these treatments can 
reduce relapse rates and severity of attacks, they do not repair immune-mediated damage to the 
myelin sheaths surrounding axons. Chronic demyelination leads to degeneration of axons and 
eventually loss of neurons. Neuronal loss correlates highly with clinical disability, highlighting 
the need for treatments that promote neuronal survival in both relapsing and progressive forms 
of MS. Experimental models of MS (both in vitro cultures and in vivo studies) have shown that 
preservation of myelin and remyelination of axons can increase neuronal survival (1, 2). To protect 
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neurons, restore function, and halt the progression of disability, 
additional treatments need to be developed to promote myelin 
repair and neuronal protection. In this article, we will review 
current concepts of effective remyelination in MS including 
proposed mechanisms of myelin regulation, emerging therapies 
that might contribute to repair and restore cell function in MS, 
and the use of magnetic resonance imaging (MRI) to measure 
remyelination in clinical trials.
FACTORS THAT CONTRiBUTe TO 
ReMYeLiNATiON FAiLURe iN MS
Understanding why endogenous remyelination often fails in MS is 
essential to the development of effective remyelination and repair 
strategies. Myelination of axons by oligodendrocytes in the CNS 
is a dynamic process determined by both the cytoarchitecture and 
microenvironment of the brain, spinal cord, and optic nerves. To 
ensure proper myelination of axons, oligodendrocytes regulate 
both their numbers and the amount of myelin each cell produces 
to properly match the number, diameter, and length of axons they 
encounter. After the completion of developmental myelination, 
many oligodendrocyte progenitor cells (OPCs) persist in the 
adult CNS. Unlike neurons, which fail to regenerate after CNS 
insult, adult OPCs are capable of proliferating and differentiating 
into mature oligodendrocytes that myelinate axons in response 
to injury or damage (3–5). Despite this regenerative ability, why 
do many axons remain demyelinated in the CNS of MS patients?
One hypothesis for remyelination failure is that the number 
of adult OPCs available for remyelination is depleted over time 
(1, 2, 4), however, post-mortem examinations of MS patients, 
including those in the seventh and eighth decades of life, revealed 
the presence of OPCs throughout the CNS, including within MS 
lesions (5–7). Nonetheless, many OPCs fail to mature into myelin-
producing oligodendrocytes. These observations suggest that the 
lesion microenvironment is prohibitive to OPC differentiation 
and subsequent remyelination of axons.
Many changes occur in areas of demyelination that could 
prevent remyelination by endogenous OPCs [reviewed by Ref. 
(8, 9)]. Disruptions to the blood–brain barrier, basal lamina dis-
turbances, and vasculature leakage occur (10–12). This leads to 
aberrant deposition of extracellular matrix (ECM) components, 
including fibronectin, hyaluronic acid (HA), and chondroitin 
sulfate proteoglycans (CSPGs), which can block the differen-
tiation of OPCs and premyelinating oligodendrocytes (8, 9, 
13–18). Demyelination can expose OPCs within lesions to other 
inhibitory cues, including components of damaged myelin such 
as the proteins MAG (myelin-associated glycoprotein), OMgp 
(oligodendrocyte myelin glycoprotein), and Nogo-A that signal 
through the Nogo receptor 1 and its co-receptors p75NTR, TROY, 
and LINGO-1 (leucine-rich repeat- and Ig domain-containing 
Nogo receptor-interacting protein 1) to inhibit both axonal 
regeneration as well as oligodendrocyte differentiation and remy-
elination (19–23). Activation of both innate CNS and peripheral 
immune cell populations leads to the release of soluble factors, 
such as pro-inflammatory cytokines, that can also negatively 
impact remyelination (24–27).
In particular, semaphorins, originally described as guidance 
molecules for axons, have been shown to play important roles 
in the regulation of remyelination. The soluble class III sema-
phorins (sema) 3A and 3F have been shown to be upregulated in 
active demyelinating but not chronic lesions in MS patients (28). 
These molecules are known to influence OPC migration, with 
sema 3A repelling OPCs and sema 3F attracting OPCs (29–31). 
Modulation of semaphorin levels within the lesion environment 
via viral overexpression impacts OPC migration and subsequent 
remyelination in animal models of demyelination suggests that 
relative levels of semaphorins in MS lesions may impact remyeli-
nation (31, 32). Interestingly, sema 3A and 3F are upregulated in 
the neuronal cell bodies of demyelinated axons far from lesions 
sites, raising the possibility that changes in demyelinated neurons 
may also influence their potential to be remyelinated (28). The 
transmembrane-bound semaphorin 4D (CD100) is normally 
expressed by mature MAG-expressing oligodendrocytes but not 
NG2-positive OPCs. Sema 4D is upregulated after injury and 
increases oligodendrocyte cell death (33, 34). Overexpression 
of sema 4D inhibits myelination in oligo-neuronal co-cultures 
while knock-down of sema 4D in a model of spinal cord injury 
(SCI) promotes functional recovery (35). Additionally, sema 4D 
expression disrupts endothelial tight junctions (35, 36). Recently, 
an antibody against sema 4D was used to treat animals in the 
experimental autoimmune encephalomyelitis (EAE) model and 
resulted in improved blood-brain barrier (BBB) integrity and 
improved OPC differentiation and axonal myelination (37). A 
phase I trial evaluating safety of a humanized anti-Sema4D IgG4 
antibody in MS patients was recently completed (38).
As lesions develop, astrogliosis, a hallmark of MS pathology, 
occurs in and around lesions, resulting in both structural and bio-
chemical changes. Astrocyte secretion of cytokines can influence 
lymphocyte infiltration (39, 40) while secretion of cytotoxic fac-
tors such as reactive oxygen and nitrogen species, glutamate, and 
ATP may directly affect oligodendrocytes and neurons (41–44). It 
is important to note that not all astrocyte changes are pathologic 
and some may even contribute to repair. For example, BDNF 
derived from astrocytes has been shown to play an important role 
in remyelination after cuprizone-induced demyelination (45). 
Astrocytes may also suppress inflammation and protect neurons 
from damaging reactive oxygen species in MS lesions via regula-
tion of mitochondrial antioxidant enzymes (46). Clearly, the role 
of astrocytes in MS pathology is a complicated one and much 
remains to be elucidated (47, 48), but reduction of astrogliosis 
has beneficial effects on remyelination in several animal models 
of demyelination (49, 50).
Disruptions in the glial–neuronal network between astrocytes, 
oligodendrocytes, and neurons also lead to metabolic deficiencies 
across cell types that cause cellular dysfunction and death (51–56). 
As neurodegeneration proceeds, unhealthy axons may no longer 
be receptive to remyelination; therefore, strategies that improve 
neuronal survival may also lead to increased remyelination, and 
importantly, improved clinical outcomes.
Several non-disease-related factors such as age, sex, diet, and 
individual genetic background can also impact the efficiency of 
remyelination (57–61). For example, with age, remyelination 
occurs more slowly due to changes in the CNS environment and 
TABLe 1 | Selected pathways and molecules that influence myelination.
Signaling 
pathway
impact on 
oligodendrocytes 
and myelination
Levels in MS Reference
Notch Spatial regulation of 
OPCs
In active MS lesions: Notch1 is 
expressed by non-differentiated 
oligodendrocytes, and Jagged1 
is expressed by hypertrophic 
astrocytes. GWAS identified 
Jagged1 as susceptibility  
gene for MS
(70–74)
Wnt Negatively regulates 
production and 
differentiation of 
oligodendrocytes. 
Inhibition of Wnt 
via Axin2 promotes 
differentiation and 
myelination
Wnt signaling and proteins are 
elevated in active MS lesions
(75–78)
Akt-mTOR Powerful positive 
regulator of myelination 
without dramatically 
impacting specification 
or proliferation of OPCs
Not determined (79–83)
Erk1/2 
MAPK
Regulates 
myelin thickness 
without impacting 
oligodendrocyte 
numbers, or 
specification, or 
differentiation
Not determined (84–86)
RXR/
PPAR
Stimulation of RXR/
PPARs inhibits 
microglial activation 
and accelerates 
remyelination
RXRγ levels are high in active 
and remyelinating lesions and 
very low in chronic inactive 
lesions
(87–89)
ISR Stress resistance and 
protection
ISR proteins CHOP, ATF4, 
and p-eIF2alpha are highly 
upregulated in MS lesions
(90–93)
mTOR, mammalian target of rapamycin; RXR, retinoic acid receptors; PPAR, 
peroxisome proliferator-activated receptor; ISR, integrated stress response.
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intrinsic epigenetic changes in oligodendrocytes, as well as age-
related changes in the immune response (60, 62–66). Another 
interesting observation is that females are at higher risk of devel-
oping MS, yet may also remyelinate more efficiently than males, 
which could be due to the differential effects of sex hormones on 
oligodendrocyte proliferation and maturation as well as on the 
neuroinflammatory process (57, 58, 67, 68).
PROPOSeD MeCHANiSMS OF CNS 
RePAiR AND ReMYeLiNATiON iN THe 
CONTeXT OF MS
There are several potential strategies to enhance the remyelina-
tion capacity of endogenous OPCs, such as manipulating intrin-
sic signaling pathways within oligodendrocytes to override the 
inhibition of remyelination or altering the lesion environment 
to be more permissive of OPC differentiation and remyelina-
tion. Transplantation to increase OPC numbers is probably not 
necessary in MS given the large numbers of OPCs present in adult 
brain tissue. Likewise, if endogenous OPCs sense injury and enter 
lesions, but cannot differentiate there, then enhancing the overall 
proliferation/migration of OPCs is unlikely to dramatically alter 
their capacity to remyelinate axons. Therefore, after dampening 
inflammation, it is crucial to support the survival and differentia-
tion of endogenous adult OPCs in order to stimulate remyelina-
tion within the altered microenvironment of MS lesions, while 
also prolonging survival of denuded axons so that they may be 
effectively remyelinated.
Modulation of intrinsic Signaling Pathways
An important approach to myelin preservation and repair is the 
pharmacological manipulation of intrinsic signaling pathways. 
Small molecules that can target specific components of the signal-
ing pathways that underlie myelination will need to be developed 
and tested. Fortunately, much has been learned about the many 
signaling pathways that govern oligodendrocyte differentiation 
and myelination over the last three decades (see Table 1). Several 
groups have recently utilized small molecules capable of modu-
lating these pathways to enhance myelination as discussed below. 
Complicating matters, however, there is a tremendous amount of 
cross-talk among signaling pathways, and manipulation of one 
pathway often induces alterations in another pathway (69). The 
high degree of cross-talk highlights the need for continued study 
of the interaction of these pathways in myelinating cells to aid 
therapeutic intervention.
Altering the extracellular environment
Unquestionably, the extracellular environment is altered in 
MS lesions, and more effective remyelination would likely be 
achieved if the local environment within lesions could be restored 
(8, 9). To this end, clearance of myelin debris and the glial scar 
produced by astrocytes may enhance remyelination. Attempts to 
modify the ECM with enzymatic digestion, particularly CSPGs 
and HA, in the context of SCI have generated favorable results 
(94–96). This is possible due to the defined local area of damage 
in SCI that is easily identified and accessed for the application of 
ECM degrading enzymes. The challenge for such an approach in 
MS is the disparate and currently unpredictable pattern of demy-
elinated regions throughout the CNS, making local delivery dif-
ficult. Therefore, strategies that directly impact cells that produce 
ECM components, such as astrocytes, or alter oligodendrocyte 
responses to aberrant ECM molecules may be more successful 
approaches.
enhancement of Cell Survival
Disruptions to glial–neuronal networks and subsequent meta-
bolic changes also impact OPCs and myelination. During acute 
demyelination, there is an increase in the mitochondrial content 
of axons early on in an attempt to keep up with the increased 
energy demands of denuded axons (97–99); however, over time 
this can lead to increased production of free radicals that can 
perpetuate axonal injury in the context of chronic demyelination 
TABLe 2 | Potential remyelinating and neuroprotective therapies in multiple sclerosis.
Drug Proposed mechanism Results Reference
Anti-ASIC-1 Blockage of ASIC-1 prevents excessive intracellular 
accumulation of injurious Na(+) and Ca(2 +) in MS 
lesions
Clinical studies suggest neuroprotection as measured by brain 
atrophy during treatment compared with pretreatment.
(105, 106)
Anti-LINGO-1 Function-blocking anti-LINGO-1 antibodies enhance 
OPC differentiation and myelination
Phase 2 trial in patients with a first episode of optic neuritis 
showed an improvement on nerve impulse conduction along  
the affected optic nerve. Phase 2 trial in RRMS is ongoing.
(107, 108)
Benztropine Antagonism of M1/M3 muscarinic acetylcholine 
receptors with subsequent stimulation of 
oligodendrocyte differentiation
In experimental models of MS, benztropine induced the 
differentiation of OPCs, and enhanced remyelination.
(109)
Guanabenz α2 adrenergic receptor agonist. Protects 
oligodendrocytes by preventing dephosphorylation  
of eIF2, increasing oligodendrocyte survival and  
prevention of myelin loss.
Preclinical studies demonstrated improvement of deficits in 
EAE. Phase I clinical studies are ongoing. 
(110, 111)
Laquinimod Modified quinolone derivative; reduces microglia and 
astrocyte activation; increases neuroprotection and 
myelin preservation
Clinical studies suggest neuroprotection as measured by  
brain atrophy in treated versus untreated patients. 
(112–117)
Miconazole and  
clobetasol
Activates eIF2, TX/RXR, and cholesterol signaling Promoted oligodendrocyte differentiation and enhanced 
remyelination in in vivo models
(118)
Olesoxime Decreases oxidative stress. Promotes oligodendrocyte 
maturation and myelin synthesis
Accelerated oligodendrocyte maturation and enhanced 
myelination in vitro and in vivo without affecting oligodendrocyte 
survival or proliferation. Phase 1 trail in MS patients completed.
(119, 120)
Quetiapine fumarate Stimulates proliferation and maturation of 
oligodendrocytes, increases neurotrophic factors,  
and inhibits activated microglia, astrocytes, and  
T lymphocytes
Remyelinating and neuroprotective properties in EAE (121, 122)
rHIgM22 rHIgM22 binds to the surface of oligodendrocytes 
promoting myelin repair
Preclinical studies indicate that it may protect oligodendrocytes 
and stimulate myelin repair. Phase I study demonstrated 
acceptable safety profile.
(123–125)
OPC, oligodendrocyte precursor cells; eIF2, Eukaryotic Initiation Factor 2; CNS, Central Nervous System; LINGO, leucine-rich repeat and immunoglobulin-like domain-containing, 
Nogo receptor-interacting protein; rHIgM22, recombinant human IgM antibody 22; EAE, experimental autoimmune encephalomyelitis; ASIC-1, acid-sensing (proton gated) ion 
channel 1.
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(100). Providing metabolic support (e.g., lactate supplementa-
tion or reducing metabolic stress signaling) could preserve both 
neurons and oligodendroglia.
Finally, it is also important to note that acute inflammation is an 
important signal that activates adult OPCs to mobilize and mature, 
but long-term inflammation can be cytotoxic to OPCs (101, 102). 
Reducing the duration of astroglial and microglial activation could 
have several beneficial effects (e.g., reducing ECM deposition and 
decreasing pro-inflammatory cytokine production), which could 
be more conducive for OPC survival, differentiation, and remy-
elination. Another potential target for therapeutic intervention is 
to increase protection of oligodendrocytes in response to inflam-
mation. Care must be taken, however, as the same signal can often 
have dual effects, either anti- or pro-inflammatory depending on 
the context. For example, silencing interferon-gamma (IFNγ) in 
astrocytes alleviates symptoms in EAE, whereas silencing of IFNγ 
in microglia increases disease severity (103).
ReMYeLiNATiON THeRAPieS iN THe 
PiPeLiNe FOR THe TReATMeNT OF MS
Remyelination Therapies
Drugs that have a positive impact on remyelination and neuropro-
tection (Table 2) could be used as part of a combination therapy, 
including immunomodulatory drugs. Treatments that enhance 
the speed of remyelination are predicted to protect neurons 
from axonal degeneration. Intervention to maintain and repair 
myelin should occur early as chronically demyelinated axons will 
degenerate precluding future remyelination by existing OPCs and 
oligodendrocytes (104).
High-throughput screens of previously FDA-approved drugs 
have identified several classes of drugs that enhance OPC differ-
entiation and myelination. Although the beneficial effects of these 
drugs on CNS cells are encouraging, careful study of off-target 
effects will need to be undertaken, given that many of these drugs 
were originally utilized for non-CNS targets. Anticholinergics, 
including the drugs benztropine (109) and clemastine (126), were 
identified in two separate high-throughput screens looking for 
agents that enhance myelination. Activation of muscarinic recep-
tors inhibits the differentiation of oligodendrocytes (127); there-
fore, the pro-myelinating effects of benztropine and clemastine are 
likely via their antagonism of M1/M3 muscarinic acetylcholine 
receptors. These anti-muscarinic compounds appear to enhance 
remyelination through direct effects on oligodendrocytes and 
not immunosuppressive effects. As phase 1 safety profile testing 
of anticholinergics has already been done for other indications, 
there has been a rapid translation of the preclinical laboratory 
findings to phase 2 clinical trials on the efficacy of clemastine in 
MS (128).
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A third small molecule screen identified two additional FDA-
approved drugs that promote oligodendrocyte differentiation and 
enhance remyelination in in vivo models (118): miconazole, an 
antifungal agent, and clobetasol, a corticosteroid used to treat 
eczema and psoriasis. Both act directly on oligodendrocytes as 
remyelinating drugs and impact eIF2 signaling, thyroid hormone 
receptor/retinoic acid receptor (TX/RXR) activation, and choles-
terol signaling. Interestingly, miconazole acts through MAPK 
signaling and has no effect on the immune system, whereas 
clobetasol acts through glucocorticoid receptor signaling and is 
also a potent immunosuppressant in addition to being a remyeli-
nating agent. With their high safety profile already established, 
approval for phase 2 trials to establish efficacy in MS could occur 
quickly.
Another strategy for promoting remyelination in MS is alter-
ing the local environment (soluble factors released by innate CNS 
cells, modifying the ECM), to be more permissive to endogenous 
OPCs. As mentioned above, the addition of enzymes, such as 
chondroitinase and hyaluronidase, is not very practical in a multi-
focal demyelinating disease such as MS. Therefore, an alternative 
approach is to change cellular responses to hostile environments. 
One promising target is the Nogo-A co-receptor LINGO-1, which 
is expressed by both neurons and oligodendrocytes. LINGO-1 
acts as a negative regulator of oligodendrocyte differentiation and 
myelination. LINGO-1 knockout mice have enhanced remyelina-
tion in several demyelination models, including EAE and toxin-
induced demyelinated lesions (23, 129, 130). Function-blocking 
anti-LINGO-1 antibodies enhance OPC differentiation and 
myelination (129). Promising results were obtained in a Phase 
2 trial of a human IgG1 anti-LINGO-1 monoclonal antibody 
(BIIB033) in patients with a first episode of optic neuritis (107). 
Treatment was well tolerated; and after 24 weeks, those patients 
given the anti-LINGO antibody had faster nerve impulse con-
duction along the optic nerve than before treatment compared 
to those on placebo, indicating myelin repair. Although visual 
evoked potentials were increased, neither visual acuity nor retinal 
neuron layer thickness were improved. Another phase 2 trial in 
patients with relapsing MS is ongoing with estimated completion 
in June 2016 (108).
Preclinical studies of a recombinant human IgM antibody 
(rHIgM22) indicate that it may protect oligodendrocytes and 
stimulate myelin repair (123, 124). rHIgM22 binds to the surface 
of oligodendrocytes, and prevents their apoptosis. Although the 
exact target is not known, rHIgM22 may bind αvß3 integrins, 
the vitronectin/fibronectin receptor, and aggregated fibronectin 
has been shown to inhibit OPC differentiation and remyelination 
(131, 132). rHIgM22 also seems to inhibit OPC differentiation, 
so how it promotes myelin repair remains unclear. rHIgM22 was 
found safe and tolerable in Phase 1 clinical trials after a 6-month 
follow-up of a single dose of patients who remained on their exist-
ing MS treatments (133). A second dose-escalating phase 1 trial 
is underway (125).
Oligodendrocytes have very high metabolic demands due to 
production of extensive amounts of lipid-rich myelin membrane. 
This makes oligodendrocytes particularly sensitive to disruptions 
in metabolic homeostasis. Hypoxia/ischemia, oxygen–glucose 
deprivation, viral infections, and high rates of protein synthesis 
in the endoplasmic reticulum (ER) can all lead to ER stress, 
which activates pancreatic ER kinase (PERK) phosphorylation 
of eukaryotic translation initiation factor 2α (eIF2α) and the 
integrated stress response (ISR) (90). The ISR inhibits global 
protein synthesis to reduce the load on the ER and also 
upregulates transcription factors, such as STF4, CHOP, ATF4, 
and p-eIF2σ that cause the cell to be in a more stress-resistant 
state. Upregulation of these ISR targets is seen in MS lesions, 
with increased PERK activity in oligodendrocytes (91). 
Enhancement of the ISR in oligodendrocytes could protect 
them and lead to increased remyelination efficiency.
Guanabenz is an α2 adrenergic receptor agonist that has been 
previously approved by the FDA for the treatment of hyperten-
sion (134). Guanabenz alleviates symptoms in EAE, increases 
oligodendrocyte survival, and reduces CD4+ T cell accumula-
tion in the CNS (110). Guanabenz appears to work by protecting 
oligodendrocytes against the inflammatory CNS environment. 
Guanabenz enhances the protective ISR of oligodendrocytes by 
preventing dephosphorylation of eIF2α, increasing oligoden-
drocyte survival, and protecting against myelin loss (110, 135). 
A phase 1 safety trail of oral guanabenz in MS patients recently 
began recruiting patients (111).
Olesoxime, is a cholesterol-oxime compound and mitochon-
drial pore modulator, originally developed to treat amyotrophic 
lateral sclerosis that targets proteins of the outer mitochondrial 
membrane, preventing permeability and decreasing oxidative 
stress (136). Olesoxime accelerates oligodendrocyte maturation 
and enhanced myelination in vitro and in vivo without affecting 
oligodendrocyte survival or proliferation (119). A phase 1b study 
in MS is ongoing (120).
Stem cell-based remyelinating therapies are also a plausible 
alternative strategy in MS as stem cells of both neural and mesen-
chymal origin have the ability to facilitate endogenous reparative 
processes, participate directly in remyelination, and attenuate 
neuroinflammation. However, there are crucial questions that 
have to be addressed before considering clinical studies, includ-
ing the determination of the optimal cellular platform, the route 
of cell delivery, and candidate patients for treatment (137).
Neuroprotective Strategies
In order to achieve maximal levels of remyelination, therapies 
that decrease axonal degeneration and increase neuronal survival 
in response to demyelination could be used to extend the period 
during which axons could be remyelinated.
Quetiapine fumarate is an atypical antipsychotic that has been 
shown to have both remyelinating and neuroprotective properties 
in EAE (121). It appears to impact various biological pathways 
relevant in MS with potential to stimulate proliferation and matu-
ration of oligodendrocytes, release of neurotrophic factors, and 
inhibit activated microglia, astrocytes, and T lymphocytes (121). 
A dose-finding trial in both relapsing and progressive forms of 
MS is underway (122).
The acid-sensing ion channel, ASIC-1, contributes to the exces-
sive intracellular accumulation of injurious Na(+) and Ca(2+) 
and is over-expressed in acute MS lesions. Blockade of ASIC1 
through amiloride, a potassium-sparing diuretic that is currently 
licensed for hypertension and congestive cardiac failure, showed 
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neuroprotective and myeloprotective effects in experimental 
models of MS (105, 106). A pilot study in primary progressive MS 
showed positive effects on brain volume (105) and a multi-arm 
randomized Phase II trial in secondary progressive MS patients 
is currently enrolling (138).
Promising results have been achieved with laquinimod, a small 
molecule that in addition to its effects on lymphocytes can also 
reduce glial reactivity (139, 140). Although the exact mechanism 
of action is not known, laquinimod, a modified quinoline deriva-
tive, appears to have direct effects on astrocytes and microglia/
macrophages within the CNS (49, 117, 139, 140). This modula-
tion of astrocyte and microglia responses appears to provide a 
protective effect on both neuronal function and oligodendrocytes 
and myelin within lesion areas (112, 141, 142). In phase 3 clinical 
trials of relapsing-remitting MS patients, both clinical disability 
and brain atrophy were reduced with laquinimod treatment 
indicative of a neuroprotective effect (113, 114, 143). A phase 
2 trial for laquinimod in primary progressive MS is underway 
(115).
ASSeSSMeNT OF ReMYeLiNATiON iN 
CLiNiCAL STUDieS
One of the biggest difficulties in the development of remyelina-
tion therapies for MS is the demonstration of remyelination 
in living patients. Indirect measures, such as improvements in 
neurophysiological outcomes, such as electroencephalography, 
evoked potentials, optical coherence tomography, and transcra-
nial magnetic stimulation may suggest, yet not confirm, remy-
elination (144–148). Functional improvements could indicate 
remyelination, but could also indicate neuronal plasticity or the 
spreading of sodium channels into demyelinated internodes, 
which could also restore conduction in unmyelinated axons 
(144, 149, 150). Although an extensive discussion is beyond 
the scope of this review, analysis of serum and cerebrospinal 
fluid (CSF) biomarkers could provide important and specific 
information regarding remyelination and repair in the future. At 
present, candidate biomarkers appear to relate to disease activity 
(interleukin-6 or its soluble receptor, nitric oxide and nitric oxide 
synthase, osteopontin, and fetuin-A) or neurodegeneration and 
blood–brain barrier dysfunction (neurofilaments, tau, 14-3-3 
proteins, S-100β, GFAP), rather than repair [for review, see in 
Ref. (151, 152)]. Even post-mortem, histopathologic approaches 
to detect remyelination are inherently limited to a “snapshot” 
assessment of the fluctuating process of demyelination and 
remyelination (153).
Demyelinating lesions are readily detected by T2-weighted 
(T2W) and fluid attenuated inversion recovery (FLAIR) MRI 
(154–156). Unfortunately, these sequences are unable to differen-
tiate remyelination from the ever-changing milieu of local inflam-
mation, edema, and axonal and myelin damage (153, 157–159). 
In addition, the correlation between MRI-identified lesion load 
and clinical disability is weak, a phenomenon referred to as the 
“clinical-radiologic paradox” in MS (160). With the increasing 
interest in development of new therapies for MS targeting remy-
elination, accurate MRI measures of myelin repair are crucial for 
assessing the impact of these therapies (161). Advancements in 
MRI technology may provide an opportunity for in vivo assess-
ment of this dynamic process in both visible lesions and the 
putatively “normal appearing white matter (NAWM).” Candidate 
imaging sequences must be sensitive and specific for changes 
occurring in vivo, correlate with other indicators of remyelina-
tion, and crucially for quantitative MRI, must be reproducible 
across imaging platforms.
ASSeSSMeNT OF ReMYeLiNATiON BY 
ADvANCeD iMAGiNG
Diffusion Tensor imaging
Diffusion tensor imaging (DTI) tracks the Brownian motion of 
water molecules in tissue to provide quantitative data about tissue 
microstructure, and is particularly well-suited to highly ordered 
environments such as CNS white matter (162). For different 
aspects of white matter microstructure, DTI produces various 
quantitative indices, including fractional anisotropy, mean diffu-
sivity, axial diffusivity, and radial diffusivity. Fractional anisotropy 
reflects the overall vector of diffusion of water molecules and, by 
inference, the directionality of the fiber tracts, while mean diffu-
sivity represents the overall magnitude of diffusion, regardless of 
direction (162). Both mean diffusivity and fractional anisotropy 
correlate with the number of axons and the degree of myelination 
in post-mortem examination, but it is difficult, if not impossible, 
to distinguish remyelination from demyelination using these 
metrics (163, 164). In highly ordered white matter bundles, 
radial diffusivity is thought to represent the diffusion of water 
molecules perpendicular to fiber tracts, while axial diffusivity is 
thought to represent the diffusion of water molecules parallel to 
the tract, and it has been suggested that radial diffusivity might 
be more sensitive to myelin damage while axial diffusivity may 
be more sensitive to axonal injury (164–167). While this appears 
promising, the major limitation of the radial and axial diffusivity 
indices is that the models used for derivation depend on accu-
rate calculation of the correct fiber tract orientation. Crossing 
fibers and disruption of the white matter microstructure by 
varying pathology in MS (pro-inflammatory cellular infiltration, 
edema, demyelination, and axonal loss) may result in inaccurate 
determination of the diffusion tensor and underestimation of 
radial diffusivity, leading to underestimation of the degree of 
changes in myelination (168–171). Newer techniques such as 
high angular resolution diffusion imaging, which is capable of 
resolving crossing fibers (172), and neurite orientation dispersion 
and density imaging, which is more specific for myelination than 
standard DTI indices (173), may increase the specificity of these 
more advanced techniques to serve as biomarkers for tracking 
remyelination in MS.
Magnetization Transfer imaging
Magnetization transfer (MT) imaging exploits the exchange 
of magnetization that occurs between two “pools” of protons 
in vivo: a “free” pool of protons that are generally unbound in 
an aqueous environment, and a “restricted” pool of protons 
that are bound to high molecular weight molecules such as 
FiGURe 1 | Magnetization transfer imaging. Axial FLAIR (A) 
demonstrating a large demyelinating lesion in the white matter posterior to 
the Sylvian fissure. Magnetization transfer image (B) demonstrates a band of 
normal white matter signal intensity across the mid aspect of the lesion (solid 
arrow) compatible with partial remyelination.
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lipids and proteins (174, 175). While signal on conventional 
imaging is predominantly derived from the relaxation of 
protons in the “free” pool; in MT imaging, two sets of images 
are obtained (one with MT-weighting, and the other without) 
allowing imaging of both pools. An estimate of the magneti-
zation transfer ratio (MTR) between these two pools can be 
calculated allowing for discrimination of subtle changes not 
picked up by conventional MRI.
Although edema, inflammation, and axonal density do 
influence MTR, the high lipid content of myelin strongly affects 
the MTR (170, 176–178), allowing MT imaging to be relatively 
sensitive in detecting changes in myelination, including remy-
elination (Figure  1). White matter lesions have a lower MTR 
than NAWM, and NAWM in MS patients has a lower MTR than 
NAWM in controls (179–181). There is also variation between 
disease subtypes: secondary progressive MS has the lowest white 
matter MTR measures, followed by relapsing-remitting MS, and 
clinically isolated syndrome (CIS) (181). Remyelinated lesions 
have higher MTR than unmyelinated lesions, but MTR in remy-
elinated lesions remains lower than NAWM (153, 182–184), 
suggesting either that remyelination is incomplete or that 
newly formed myelin in lesions has a different structure, which 
is consistent with reports of thinner myelin in post-mortem 
examination of remyelinated lesions (185). While lesions appear 
generally static on conventional imaging over time, MTR fluctu-
ates within lesions, suggesting alternating waves of both demy-
elination and remyelination (184). Given the semi-quantitative 
nature of MTR measurement, recent efforts have been made to 
directly measure the size and relaxation characteristics of the 
“restricted” proton pool, to provide quantitative measurements 
that are even more strongly influenced by myelin in the brain 
(186–190). Although performing multiple MT-weighted acqui-
sitions increases scan times, MT imaging could be advantageous 
in large clinical trials as quantitative metrics are more consistent 
across scanners.
Myelin water Fraction imaging
Brain tissue microstructure is complex and each tissue compo-
nent displays different T2 relaxation characteristics. The differ-
ences in T2 relaxation correlate with water separated into three 
components: a long T2 component corresponding to CSF, an 
intermediate T2 component corresponding to intra/extracellular 
water, and a short T2 relaxation time component corresponding 
to water trapped with layers of myelin (191). Of most interest 
in MS is the short T2 (myelin water) component, measured as 
the ratio of myelin water to the total water, i.e., the myelin water 
fraction (MWF). Histopathological studies have shown that the 
MWF correlates with myelin content, is insensitive to changes 
related to inflammation, and is independent of axonal loss/
degeneration (186, 192).
Early techniques for measuring MWF depended on 2D 
multi-spin echo acquisitions, which due to time considerations 
permitted only incomplete coverage of the brain. To improve 
brain coverage and further reduce MT effects, other sequences 
are now available, including 3D-GRASE and most recently 
mcDESPOT, which allow coverage of the entire brain within rea-
sonable acquisition times (157, 193, 194). While these techniques 
show much promise, work still needs to be done to confirm their 
tissue specificity. One recent study, for instance, indicated that in 
white matter mcDESPOT may not be able to precisely estimate 
the two-pool model with exchange (195). Despite that limitation, 
MWF is lower in MS patients compared to that of controls (196), 
correlates with disability, and decreases over time in patients with 
progressive MS (197). MWF imaging has the potential to follow 
remyelination in lesions after acute edema has resolved (198) and 
has been shown to increase in patients treated with alemtuzumab, 
suggesting it may be useful in monitoring for remyelination in 
treated patients (199).
Positron emission Tomography
Positron emission tomography (PET) uses radioisotopes that 
directly bind to different tissue substrates to enable molecular 
imaging. Direct binding of imaging biomarkers specific for myelin 
could potentially far exceed the specificity of the other modali-
ties discussed above and allow investigators to detect changes 
specific for myelin content in the brain. One such biomarker 
is the thioflavine-T derivative 2-(4′-methylaminophenyl)-
6-hydroxybenzothiazole (PIB). 11C-PIB is currently used in the 
imaging of Alzheimer’s disease (200, 201) but recent studies have 
shown that in addition to amyloid plaques, PIB also has an affinity 
for CNS myelin and demonstrates differential binding to normal 
and demyelinated white matter (202, 203). In two RRMS patients, 
11C-PIB uptake was less in enhancing lesions (203), indicating 
that there may be differences in the myelination of lesions at 
different stages. While promising, additional studies of more MS 
patients are required to validate these findings and not all centers 
will have access to such technology.
CONCLUSiON
Repair and remyelination in MS is possible, but remyelina-
tion often fails as a consequence of failure to recruit OPCs 
fully into the lesions, failure of OPCs to generate mature 
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myelinating oligodendrocytes, and failure of oligodendrocytes 
to  remyelinate axons. Several candidates to enhance remy-
elination are currently under investigation with a variety of 
mechanisms of action. One barrier to evaluating remyelination 
therapies in patients is the lack of methods to accurately detect 
myelination, demyelination, and remyelination with standard 
imaging technologies. Advancements in MRI technology allow 
better detection of myelin-specific changes but criteria that 
can be readily quantified using new imaging technologies will 
have to be established and validated to determine the success of 
remyelination in clinical trials.
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